Drug-Eluting Stents: A Promising Solution for Intracranial Atherosclerosis?
"Find out how these innovative stents offer a safer, more effective approach to treating blocked arteries in the brain and preventing stroke."
Intracranial atherosclerotic disease (ICAD), a major cause of stroke worldwide, especially among Asians, Blacks, and Hispanics, involves the narrowing of arteries within the brain. Traditional treatments for symptomatic ICAD (sICAD) have been evolving, but new solutions are needed. The WASID and SAMMPRIS trials highlighted the challenges and limitations of medical management and traditional stenting procedures.
While aggressive medical management and risk factor control are essential, some patients require more. Percutaneous transluminal angioplasty and stenting (PTAS) techniques have been explored; self-expanding stents (SES) and bare metal stents (BMS) were common. However, the SAMMPRIS and VISSIT trials were stopped early because the stent groups showed increased perioperative complications and no long-term benefit.
The problem? In-stent restenosis (ISR), the re-narrowing of the artery after stenting. Drug-eluting stents (DES), widely used in coronary artery disease, slowly release medication to inhibit cell growth and reduce ISR. Now, researchers are exploring DES for ICAD to improve outcomes. This article examines a systematic review and meta-analysis of DES for ICAD, assessing their efficacy and safety compared to other treatments.
Intracranial DES: Current Evidence
A 2019 source describes drug-eluting stents (DES) as balloon-expandable systems that slowly release paclitaxel or sirolimus into the vessel wall, aiming to inhibit cell proliferation and migration and thereby reduce neointimal hyperplasia and in-stent restenosis (ISR). A 2026 study set out to evaluate intracranial DES for intracranial atherosclerotic stenosis (ICAS)-related emergent large vessel occlusion, including safety and short-term prognosis; the provided summary does not report its results. The listed materials therefore describe the treatment rationale and a research objective, but provide no current population-level impact statistics.
Medical Therapy and Endovascular Questions
A 2026 review reports that international guidelines have recommended drug therapy as first-line treatment for symptomatic intracranial atherosclerotic disease (ICAD) for almost 10 years, citing issues with endovascular treatment. A randomized clinical trial published in 2022 compared DES with standard bare-metal stents (BMS) in patients with symptomatic high-grade intracranial atherosclerotic stenosis, assessing ISR and recurrent stroke. The supplied summaries do not provide the trial’s results, so they establish the comparison being studied rather than showing that either stent type is superior.
The Evolution of Drug-Eluting Stents
A 2022 review examines the history, research hotspots, and emerging trends of drug-eluting stents (DES) over the preceding two decades, using publications retrieved from the Web of Science Core Collection. Another review describes DES as limiting problems associated with uncovered bare-metal stents after coronary interventions, while noting continuing concerns about late stent thrombosis and in-stent restenosis. It also reports that second-generation DES appeared to lessen these concerns compared with first-generation devices. These sources discuss DES history broadly and do not establish a specific milestone in intracranial stenting.
Do Drug-Eluting Stents Reduce Complications and Improve Outcomes?
To evaluate the effectiveness of DES for ICAD, researchers conducted a thorough review of medical literature. They analyzed 13 studies involving 336 patients (364 lesions) treated with DES, focusing on key outcomes:
- Perioperative Complications: Occurred in 6.0% of patients.
- Long-Term Complications: Occurred in 2.2% of patients.
- In-Stent Restenosis (ISR): 4.1% of patients experienced ISR.
- Symptomatic ISR: Only 0.5% of patients had symptomatic ISR.
Evidence on DES, Restenosis, and Procedural Risk
A 2025 meta-analysis reported a 4.1% in-stent restenosis rate across 364 ICAS lesions treated with DES, drawing on 13 studies. A separate review of stent-based interventions notes possible higher procedural morbidity from technical challenges, including vessel-wall perforation or distal-branch injury during guidewire exchanges and the stiff profiles of balloon-expandable stents. These findings highlight both a reported restenosis outcome and potential procedural hazards; the supplied summaries do not establish a direct comparison between them.
Persistent Concerns in Endovascular Treatment
A 2026 review states that international guidelines have recommended drug therapy as first-line treatment for symptomatic ICAD for almost 10 years because of issues associated with endovascular treatment. It also reports that endovascular ICAD treatment has progressed and periprocedural complication rates have fallen. However, the excerpt flags early in-stent restenosis as an ongoing concern and does not provide a rate or further outcome details. The source therefore presents both procedural progress and a continuing limitation, without quantifying the balance between them.
DES Compared With Bare-Metal Stents
A meta-analysis published on April 9, 2024, set out to compare the efficacy of drug-eluting stents (DES) and bare-metal stents (BMS) for intracranial atherosclerotic stenosis (ICAS). Its stated background says evidence supports DES efficacy over BMS in the setting of ICAS. The supplied summary does not give comparative effect estimates or specific outcomes, so it supports reporting the review’s stated direction but not quantifying the advantage.
The Future of ICAD Treatment: What Does This Mean for You?
This review suggests that drug-eluting stents are a relatively safe and effective option for treating intracranial atherosclerotic disease, offering improved outcomes compared to older stent designs and medical management alone.
Stents and Drug-Coated Balloons
A 2026 review describes stent angioplasty as the most common endovascular intervention for intracranial atherosclerotic stenosis (ICAS), particularly when medical therapy has not succeeded, while noting risks including restenosis and thromboembolic events. It presents drug-coated or drug-eluting balloons (DCB/DEBs) as a promising alternative. A separate 2024 review argues that advances in arterial stenting have challenged earlier conclusions favoring medical management and says recent studies suggest DES may be favorable because of their antiproliferative effect. Together, these sources describe evolving options and arguments, but the excerpts do not establish a definitive treatment recommendation.
Recurrent Ischemic Risk and Treatment Constraints
A 2024 report says patients with intracranial in-stent restenosis (ISR) are at high risk of recurrent ischemic events. It reports that the NOVA intracranial drug-eluting stent trial found DES can reduce ISR and stroke recurrence after implantation of an intracranial bare stent. The same source cautions that use of balloon-expanded DES requires specific vascular conditions. The provided summary does not specify those conditions or quantify the reported reductions.
However, the increased risk of perioperative complications in patients with severe stenosis highlights the need for careful patient selection and experienced operators. More research is needed to confirm these findings and optimize the use of DES in ICAD.
If you're at risk for or have been diagnosed with ICAD, talk to your doctor about the best treatment options for you. Drug-eluting stents may offer a promising solution, but the decision should be made in consultation with a qualified medical professional who can assess your individual risk factors and determine the most appropriate course of action.